Literature DB >> 26920890

Therapeutic Guide for mTOuRing through the Braided Kidney Cancer Genomic River.

Martin H Voss1, James J Hsieh2.   

Abstract

mTORC1 inhibitors were first approved for the use in metastatic kidney cancer. However, observed treatment benefit was highly heterogeneous among patients. Through case-based cancer genomic sequencing of therapeutic outliers, we can begin to appreciate the convergent evolution of given cancer pathways/phenotypes beyond genes in kidney cancer, like a braided river. Clin Cancer Res; 22(10); 2320-2. ©2016 AACRSee related article by Kwiatkowski et al., p. 2445. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26920890      PMCID： PMC5431075          DOI： 10.1158/1078-0432.CCR-16-0035

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.

Authors:  Brian C Grabiner; Valentina Nardi; Kıvanc Birsoy; Richard Possemato; Kuang Shen; Sumi Sinha; Alexander Jordan; Andrew H Beck; David M Sabatini
Journal:  Cancer Discov       Date:  2014-03-14       Impact factor: 39.397

Review 2.  mTOR inhibitors in advanced renal cell carcinoma.

Authors:  Martin H Voss; Ana M Molina; Robert J Motzer
Journal:  Hematol Oncol Clin North Am       Date:  2011-08       Impact factor: 3.722

3.  Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Carlos H Barrios; Tae Min Kim; Silvia Falcon; Thomas Cosgriff; W Graydon Harker; Vichien Srimuninnimit; Ken Pittman; Roberto Sabbatini; Sun Young Rha; Thomas W Flaig; Ray Page; Sevil Bavbek; J Thaddeus Beck; Poulam Patel; Foon-Yiu Cheung; Sunil Yadav; Edward M Schiff; Xufang Wang; Julie Niolat; Dalila Sellami; Oezlem Anak; Jennifer J Knox
Journal:  J Clin Oncol       Date:  2014-07-21       Impact factor: 44.544

4.  Kidney cancer, version 3.2015.

Authors:  Robert J Motzer; Eric Jonasch; Neeraj Agarwal; Clair Beard; Sam Bhayani; Graeme B Bolger; Sam S Chang; Toni K Choueiri; Brian A Costello; Ithaar H Derweesh; Shilpa Gupta; Steven L Hancock; Jenny J Kim; Timothy M Kuzel; Elaine T Lam; Clayton Lau; Ellis G Levine; Daniel W Lin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Elizabeth R Plimack; Edward N Rampersaud; Bruce G Redman; Charles J Ryan; Joel Sheinfeld; Brian Shuch; Kanishka Sircar; Brad Somer; Richard B Wilder; Mary Dwyer; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2015-02       Impact factor: 11.908

5.  A clear picture of renal cell carcinoma.

Authors:  A Ari Hakimi; Can G Pham; James J Hsieh
Journal:  Nat Genet       Date:  2013-08       Impact factor: 38.330

Review 6.  A river model to map convergent cancer evolution and guide therapy in RCC.

Authors:  Elizabeth Y Wei; James J Hsieh
Journal:  Nat Rev Urol       Date:  2015-11-03       Impact factor: 14.432

7.  Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.

Authors:  Martin H Voss; A Ari Hakimi; Can G Pham; A Rose Brannon; Ying-Bei Chen; Luis F Cunha; Oguz Akin; Han Liu; Shugaku Takeda; Sasinya N Scott; Nicholas D Socci; Agnes Viale; Nikolaus Schultz; Chris Sander; Victor E Reuter; Paul Russo; Emily H Cheng; Robert J Motzer; Michael F Berger; James J Hsieh
Journal:  Clin Cancer Res       Date:  2014-03-12       Impact factor: 12.531

8.  Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.

Authors:  David J Kwiatkowski; Toni K Choueiri; Sabina Signoretti; André P Fay; Brian I Rini; Aaron R Thorner; Guillermo de Velasco; Magdalena E Tyburczy; Lana Hamieh; Laurence Albiges; Neeraj Agarwal; Thai H Ho; Jiaxi Song; Jean-Christophe Pignon; Pablo M Barrios; M Dror Michaelson; Eliezer Van Allen; Katherine M Krajewski; Camillo Porta; Sumanta Pal; Joaquim Bellmunt; David F McDermott; Daniel Y C Heng; Kathryn P Gray
Journal:  Clin Cancer Res       Date:  2016-02-01       Impact factor: 12.531

9.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

10.  The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.

Authors:  Alexander Sankin; Abraham A Hakimi; Nina Mikkilineni; Irina Ostrovnaya; Mikhail T Silk; Yupu Liang; Roy Mano; Michael Chevinsky; Robert J Motzer; Stephen B Solomon; Emily H Cheng; Jeremy C Durack; Jonathan A Coleman; Paul Russo; James J Hsieh
Journal:  Cancer Med       Date:  2014-08-14       Impact factor: 4.452
View more
  10 in total

1.  Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples.

Authors:  Yiyu Dong; Brandon J Manley; Maria F Becerra; Almedina Redzematovic; Jozefina Casuscelli; Daniel M Tennenbaum; Ed Reznik; Song Han; Nicole Benfante; Ying-Bei Chen; Maria E Arcila; Omer Aras; Martin H Voss; Darren R Feldman; Robert J Motzer; Nicola Fabbri; John H Healey; Patrick J Boland; Mohit Chawla; Jeremy C Durack; Chung-Han Lee; Jonathan A Coleman; Paul Russo; A Ari Hakimi; Emily H Cheng; James J Hsieh
Journal:  Eur Urol Focus       Date:  2016-08-25

2.  Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.

Authors:  Jianing Xu; Can G Pham; Steven K Albanese; Yiyu Dong; Toshinao Oyama; Chung-Han Lee; Vanessa Rodrik-Outmezguine; Zhan Yao; Song Han; David Chen; Daniel L Parton; John D Chodera; Neal Rosen; Emily H Cheng; James J Hsieh
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

3.  The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.

Authors:  Amrita M Nargund; Can G Pham; Yiyu Dong; Patricia I Wang; Hatice U Osmangeyoglu; Yuchen Xie; Omer Aras; Song Han; Toshinao Oyama; Shugaku Takeda; Chelsea E Ray; Zhenghong Dong; Mathieu Berge; A Ari Hakimi; Sebastien Monette; Carl L Lekaye; Jason A Koutcher; Christina S Leslie; Chad J Creighton; Nils Weinhold; William Lee; Satish K Tickoo; Zhong Wang; Emily H Cheng; James J Hsieh
Journal:  Cell Rep       Date:  2017-03-21       Impact factor: 9.423

4.  Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.

Authors:  James J Hsieh; David Chen; Patricia I Wang; Mahtab Marker; Almedina Redzematovic; Ying-Bei Chen; S Duygu Selcuklu; Nils Weinhold; Nancy Bouvier; Kety H Huberman; Umesh Bhanot; Michael S Chevinsky; Parul Patel; Patrizia Pinciroli; Helen H Won; Daoqi You; Agnes Viale; William Lee; A Ari Hakimi; Michael F Berger; Nicholas D Socci; Emily H Cheng; Jennifer Knox; Martin H Voss; Maurizio Voi; Robert J Motzer
Journal:  Eur Urol       Date:  2016-10-15       Impact factor: 20.096

Review 5.  Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.

Authors:  James J Hsieh; Brandon J Manley; Nabeela Khan; JianJiong Gao; Maria I Carlo; Emily H Cheng
Journal:  Semin Cell Dev Biol       Date:  2016-09-08       Impact factor: 7.727

6.  Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.

Authors:  Maria F Becerra; Ed Reznik; Almedina Redzematovic; Daniel M Tennenbaum; Mahyar Kashan; Mazyar Ghanaat; Jozefina Casuscelli; Brandon Manley; Philip Jonsson; Renzo G DiNatale; Kyle A Blum; Jeremy C Durack; Stephen B Solomon; Maria E Arcila; Caitlin Bourque; Nick Socci; Maria I Carlo; Chung-Han Lee; Martin H Voss; Darren R Feldman; Robert J Motzer; Jonathan A Coleman; Paul Russo; Emily H Cheng; A Ari Hakimi; James J Hsieh
Journal:  Eur Urol Focus       Date:  2017-10-20

7.  A braided cancer river connects tumor heterogeneity and precision medicine.

Authors:  James J Hsieh; Emily H Cheng
Journal:  Clin Transl Med       Date:  2016-10-20

8.  Renal Cell Carcinoma With Urinary Bladder Metastasis: A Case Report With Metachronous Genomic Analyses.

Authors:  Alexander Chehrazi-Raffle; Jasnoor Malhotra; Sabrina Salgia; Crystal Favorito; JoAnn Hsu; Huiqing Wu; Sumanta K Pal
Journal:  JCO Precis Oncol       Date:  2021-03-26

9.  Diagnostic and prognostic role of basic leucine zipper transcription factor in kidney renal clear cell carcinoma.

Authors:  Hui Zhang; Hui Zhang; Yiming Hu; Bin Huang; Junxing Chen; Lingwu Chen
Journal:  Transl Androl Urol       Date:  2022-02

Review 10.  Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice.

Authors:  Jozefina Casuscelli; Yann-Alexandre Vano; Wolf Herve Fridman; James J Hsieh
Journal:  Kidney Cancer       Date:  2017-07-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.